DDInter1716 DDInter1676
Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short medical procedures requiring brief periods of muscle relaxation.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Succinylcholine {u} (Compound) resembles {v} (Compound) Carbachol
Succinylcholine {u} (Compound) resembles {v} (Compound) Decamethonium
Succinylcholine {u} (Compound) binds {v} (Gene) CHRND
Succinylcholine {u} (Compound) is included by {v} (Pharmacologic Class) Neuromuscular Depolarizing Blockade
Succinylcholine {u} (Compound) causes {v} (Side Effect) Respiratory failure
Succinylcholine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Irinotecan
Succinylcholine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Physostigmine
Succinylcholine {u} may lead to a major life threatening interaction when taken with {v} Neomycin
Succinylcholine (Compound) resembles Carbachol (Compound)
Succinylcholine (Compound) resembles Decamethonium (Compound)
Succinylcholine (Compound) binds CHRND (Gene)
Succinylcholine (Compound) is included by Neuromuscular Depolarizing Blockade (Pharmacologic Class)
Succinylcholine (Compound) causes Respiratory failure (Side Effect)
Succinylcholine may cause a minor interaction that can limit clinical effects when taken with Irinotecan
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Succinylcholine may lead to a major life threatening interaction when taken with Neomycin